The increased FPR2 mRNA expression in RA PBMC, coupled with the distinct pro-resolving function of the selective FPR2 agonist highlighted in this study, positions FPR2 agonists as a promising therapeutic avenue for addressing CVD in RA (Lupisella et al, 2022; Chen et al, 2021). The gene discussed is FPR2; the disease is rheumatoid arthritis.